Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beam Therapeutics (BEAM) EBIT Margin: 2019-2025

Historic EBIT Margin for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to -1,307.60%.

  • Beam Therapeutics' EBIT Margin fell 56120.00% to -1,307.60% in Q3 2025 from the same period last year, while for Sep 2025 it was -837.12%, marking a year-over-year decrease of 78488.00%. This contributed to the annual value of -654.25% for FY2024, which is 60753.00% down from last year.
  • Beam Therapeutics' EBIT Margin amounted to -1,307.60% in Q3 2025, which was up 7.86% from -1,419.22% recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' EBIT Margin peaked at 42.02% during Q4 2023, and registered a low of -3,339,550.00% during Q1 2021.
  • Moreover, its 3-year median value for EBIT Margin was -746.40% (2024), whereas its average is -836.66%.
  • In the last 5 years, Beam Therapeutics' EBIT Margin tumbled by 286,696,667bps in 2021 and then skyrocketed by 333,864,600bps in 2022.
  • Quarterly analysis of 5 years shows Beam Therapeutics' EBIT Margin stood at -124.31% in 2021, then slumped by 31,979bps to -444.10% in 2022, then surged by 48,612bps to 42.02% in 2023, then tumbled by 37,473bps to -332.71% in 2024, then plummeted by 56,120bps to -1,307.60% in 2025.
  • Its last three reported values are -1,307.60% in Q3 2025, -1,419.22% for Q2 2025, and -1,596.87% during Q1 2025.